Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

TKI tolerance

  • Emma Sedgwick
  • Emma Sedgwick's Avatar Topic Author
1 day 7 hours ago - 22 hours 25 minutes ago #2086 by Emma Sedgwick
TKI tolerance was created by Emma Sedgwick
51 year old CP CML diagnosed 2017. On 6th line Ponatinib. Had all TKIs and Asciminib (Asciminib worst for side effects) but all stopped due to severe joint, and muscle pain causing disability. Started Ponatinib Sept 2023 15mg 3x weekly with good response and MMR. Initially had no pain and tolerated well. Now has severe joint and muscle pain and hypertension even on 15mg weekly Ponatinib. Due to treatment breaks and low dosage, BCR ABL has now risen to 5%. Will respond to increasing Ponatinib but at cost of patient disability. No KD mutations and has no issues with treatment failure, only tolerance. Declined allograft. Patient is a self employed builder. No other medical history and no other cause for pain. Pain stops with cessation of TKI after several weeks then recurs immediately on restarting. How can we manage this patient? 
Last edit: 22 hours 25 minutes ago by arlene.
Quick Reply

Reply to Emma Sedgwick

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
22 hours 20 minutes ago #2087 by Tim Hughes
Replied by Tim Hughes on topic TKI tolerance
This is an unusual situation – out of about 500 patients we manage in Adelaide there are 2 or 3 with a similar story to this - severe joint/muscle pains with any TKI. I am assuming this patient has never had resistance – just intolerance that has been the cause of his multiple switches. I don’t think ponatinib is a great choice for a patient with intolerance problems – it hits so many targets that can cause intolerance as well as toxicity. My preference would be to use the most highly targeted drug available – asciminib or another allosteric TKI. Surprisingly he had the worst side effects on asciminib – I have never seen this. It would be interesting to see how he tolerated one of the other TKIs in clinical development which is highly targeted – I would certainly try that if it was available on trial (Tern -701, TGRX-678, or Enliven). If that is not possible I would abandon the ponatinib – it is not working at a tolerable dose. I would probably try low dose dasatinib – 50 mg/day initially planning to go lower if mol response (MMR) is restored and side effects are still significant. No easy answers here I am afraid.
Quick Reply

Reply to Tim Hughes

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene